Clinical trials show that treatment with IFNβ is associated with prevention of relapse compared with placebo across all relapsing subtypes of MS [34–36]; however, up to 30–50% of patients show suboptimal responses to therapy [37–39]. This evidence concerns the gene IFNB1 and myeloid sarcoma.